ometendoОжирение и метаболизмObesity and metabolism2071-87132306-5524Endocrinology Research Centre10.14341/2071-8713-4822ometendo-4822Research ArticleСтатьиArticlesОжирение, ассоциированное с приемом нейролептиков – роль гиперпролактинемииObesity associated with neuroleptic drugs, value of hyperprolactinemiaYunilainenO Aolga84j@yandex.ruStarostinaE Gelena.starostina@rambler.ruDzeranovaL Kdzeranovalk@yandex.ru201315062013102№2 (2013)3337Copyright © Yunilainen O.A., Starostina E.G., Dzeranova L.K., 20132013Yunilainen O.A., Starostina E.G., Dzeranova L.K.Yunilainen O.A., Starostina E.G., Dzeranova L.K.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.omet-endojournals.ru/jour/article/view/4822ReferencesДедов И.И., Мельниченко Г.А., Романцова Т.И. Синдром гиперпролактинемии. М., 2004.Дедов И.И., Мельниченко Г.А., Романцова Т.И. Синдром гиперпролактинемии. М., 2004.Дедов И.И., Мельниченко Г.А. Ожирение. М., 2006.Дедов И.И., Мельниченко Г.А. Ожирение. М., 2006.Мельниченко Г.А., Гончаров Н.П., Дзеранова Л.К., Добрачева А.Д., Бармина И.И. Клинические и лабораторные аспекты исследования изоформ пролактина методом ПЭГ-преципитации и ультрафильтрации. Проблемы эндокринологии. 2010; № 1: 19–25.Мельниченко Г.А., Гончаров Н.П., Дзеранова Л.К., Добрачева А.Д., Бармина И.И. Клинические и лабораторные аспекты исследования изоформ пролактина методом ПЭГ-преципитации и ультрафильтрации. Проблемы эндокринологии. 2010; № 1: 19–25.Holt RI, Peveler RC. Obesity, serious mental illness and antipsychotic drugs. Diabetes Obes Metab. 2009 Jul; № 11(7): 665–79.Holt RI, Peveler RC. Obesity, serious mental illness and antipsychotic drugs. Diabetes Obes Metab. 2009 Jul; № 11(7): 665–79.Roerig JL, Steffen KJ, Mitchell JE. Atypical antipsychotic-induced weight gain: insights into mechanisms of action. CNS Drugs. 2011 Dec 1; 25(12): 1035–59.Roerig JL, Steffen KJ, Mitchell JE. Atypical antipsychotic-induced weight gain: insights into mechanisms of action. CNS Drugs. 2011 Dec 1; 25(12): 1035–59.Baptista T, Kin NM, Beaulieu S, de Baptista EA. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives. Pharmacopsychiatry. 2002 Nov; 35(6): 205–19.Baptista T, Kin NM, Beaulieu S, de Baptista EA. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives. Pharmacopsychiatry. 2002 Nov; 35(6): 205–19.Neovius M, Eberhard J, Lindström E, Levander S. Weight development in patients treated with risperidone: a 5-year naturalistic study. Acta Psychiatr Scand. 2007 Apr; 115(4): 277–85.Neovius M, Eberhard J, Lindström E, Levander S. Weight development in patients treated with risperidone: a 5-year naturalistic study. Acta Psychiatr Scand. 2007 Apr; 115(4): 277–85.Eberhard J, Lindström E, Holstad M, Levander S. Prolactin level during 5 years of risperidone treatment in patients with psychotic disorders. Acta Psychiatr Scand. 2007 Apr; 115(4): 268–76.Eberhard J, Lindström E, Holstad M, Levander S. Prolactin level during 5 years of risperidone treatment in patients with psychotic disorders. Acta Psychiatr Scand. 2007 Apr; 115(4): 268–76.Baptista T, Lacruz A, Meza T, Contreras Q, Delgado C, Mejìas MA, Hernàndez L. Antipsychotic drugs and obesity: is prolactin involved? Can J Psychiatry. 2001 Nov; 46(9): 829–34.Baptista T, Lacruz A, Meza T, Contreras Q, Delgado C, Mejìas MA, Hernàndez L. Antipsychotic drugs and obesity: is prolactin involved? Can J Psychiatry. 2001 Nov; 46(9): 829–34.Baptista T, Reyes D, Hernández L. Antipsychotic drugs and reproductive hormones: relationship to body weight regulation. Pharmacol Biochem Behav. 1999 Mar; 62(3): 409–17.Baptista T, Reyes D, Hernández L. Antipsychotic drugs and reproductive hormones: relationship to body weight regulation. Pharmacol Biochem Behav. 1999 Mar; 62(3): 409–17.
The authors declare that there are no conflicts of interest present.